Orlando Health Ventures Invests $1.25M in Innovative Heart Valve Repair Device
February 21, 2020
Orlando Health Ventures has invested $1.25 million in Biostable Science & Engineering, an Austin based cardiovascular device company developing heart valve repair technologies that provide an alternative to heart valve replacement for patients.
Aortic valve insufficiency is the leaking of the aortic valve of the heart that causes blood to flow in reverse, from the aorta into the left ventricle. This forces the cardiac muscle to work harder than normal in patients with this condition and typically requires surgical intervention at a much younger age than for other heart valve conditions. Current Aortic valve repair surgical techniques are considered complex, invasive and are only available to specific subset of patients, highlighting a need for alternatives to avoid aortic valve replacement within this distinct and often under-treated population.
Biostable’s HAART device provides an alternative to mechanical and tissue valve replacement and reshapes and stabilizes the aortic valve to enable a consistent, standardized surgical approach to valve repair, enabling more widespread adoption of the procedure. The HAART device restores and maintains the valve shape to allow proper valve closure and preserves patient’s native anatomy. “Biostable’s HAART Aortic Annuloplasty device will enable a new valve repair technique to be more widely adopted with consistently reproducible results and will expand treatment options for many patients. Our team at the Orlando Health Heart & Vascular Institute is looking forward to using the device with our patients and working with Biostable to ensure valve repair is increasingly a realistic option for patients with Aortic insufficiency,” said Farhan Khawaja, MD – Cardiologist and President of the Orlando Health Heart & Vascular Institute.
The HAART product was introduced to the Orlando Health Heart & Vascular Institute team through Orlando Health Ventures, the external arm of the organization’s strategic innovations department. The program focuses on investing in and partnering with external, early stage companies whose products or services will make an impact for patients at Orlando Health. Biostable’s innovative HAART device and its growing adoption in the cardiac surgery community convinced Orlando Health to invest $1.25 million in Biostable.
“Biostable is another great example of a growing, early-stage company that offers an innovative approach and product that will benefit our patients in Central Florida, and patients across the country,” said Erick Hawkins, senior vice president of strategic management at Orlando Health. “By partnering with Biostable we are ensuring that patients with aortic insufficiency have a new treatment option that will help them return to good health, as well as providing our clinical team with access to an amazing new tool that will allow them to continue to provide the best possible care for our patients.”
Learn more about Biostable and the HAART device.